Bluejay Diagnostics (BJDX) Gains from Sales and Divestitures (2023 - 2025)

Bluejay Diagnostics has disclosed Gains from Sales and Divestitures across 3 years of filings, most recently posting $1.0 for Q3 2025.

• Gains from Sales and Divestitures for Q3 2025 came in at $1.0, down 99.89% year-over-year; the trailing twelve-month figure through Sep 2025 was $1.0 (down 99.89% YoY), and the FY2024 annual result was $18.0, down 99.91% from the prior year.
• Gains from Sales and Divestitures came in at $1.0 for Q3 2025 at Bluejay Diagnostics, roughly flat from $1.0 in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $374680.0 in Q1 2023 to a low of $1.0 in Q2 2025.
• The 3-year median for Gains from Sales and Divestitures is $3898.5 (2024), against an average of $44187.1.
• Peak annual rise in Gains from Sales and Divestitures reached 95.27% in 2024, while the deepest fall reached 99.91% in 2024.
• Bluejay Diagnostics' Gains from Sales and Divestitures stood at $19484.0 in 2023, then slumped by 99.91% to $18.0 in 2024, then sank by 94.44% to $1.0 in 2025.
• The last three Gains from Sales and Divestitures figures came in at $1.0 (Q3 2025), $1.0 (Q2 2025), and $18.0 (Q4 2024), per Business Quant data.